Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Financing Activities (2016 - 2026)

Corvus Pharmaceuticals' Cash from Financing Activities history spans 11 years, with the latest figure at $190.7 million for Q1 2026.

  • Quarterly Cash from Financing Activities rose 68267.74% to $190.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $226.9 million through Mar 2026, up 1098.16% year-over-year, with the annual reading at $36.4 million for FY2025, 25.7% down from the prior year.
  • Cash from Financing Activities came in at $190.7 million for Q1 2026, up from $20000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $190.7 million in Q1 2026 to a low of $4000.0 in Q1 2023.
  • The 4-year median for Cash from Financing Activities is $347500.0 (2023), against an average of $25.4 million.
  • Year-over-year, Cash from Financing Activities crashed 99.89% in 2025 and then skyrocketed 68267.74% in 2026.
  • Corvus Pharmaceuticals' Cash from Financing Activities stood at $335000.0 in 2023, then soared by 5454.63% to $18.6 million in 2024, then plummeted by 99.89% to $20000.0 in 2025, then skyrocketed by 953630.0% to $190.7 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Cash from Financing Activities are $190.7 million (Q1 2026), $20000.0 (Q4 2025), and $360000.0 (Q3 2025).